Technical Analysis for OTLK - Outlook Therapeutics, Inc.

Grade Last Price % Change Price Change
D 5.28 0.96% 0.05
OTLK closed up 0.96 percent on Wednesday, November 20, 2024, on 51 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
NR7 Range Contraction 0.96%
Wide Bands Range Expansion 0.96%
Oversold Stochastic Weakness 0.96%
MACD Bearish Centerline Cross Bearish 2.42%
Wide Bands Range Expansion 2.42%
Down 3 Days in a Row Weakness 2.42%
Down 4 Days in a Row Weakness 2.42%

   Recent Intraday Alerts

Alert Time
Up 3% about 22 hours ago
Rose Above Previous Day's High about 22 hours ago
Up 2% about 22 hours ago
Up 1% about 22 hours ago
Down 1% about 22 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Outlook Therapeutics, Inc. Description

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was founded in 2010 and is headquartered in Cranbury, New Jersey.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Life Sciences Antibodies Cancer Treatment Monoclonal Antibodies Monoclonal Antibody Ophthalmic Macular Degeneration Specialty Drugs Retina Wet Age Related Macular Degeneration Age Related Macular Degeneration

Is OTLK a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 12.8499
52 Week Low 4.61
Average Volume 284,114
200-Day Moving Average 7.40
50-Day Moving Average 5.64
20-Day Moving Average 5.85
10-Day Moving Average 5.83
Average True Range 0.36
RSI (14) 39.76
ADX 22.42
+DI 19.74
-DI 30.04
Chandelier Exit (Long, 3 ATRs) 5.90
Chandelier Exit (Short, 3 ATRs) 6.00
Upper Bollinger Bands 6.77
Lower Bollinger Band 4.94
Percent B (%b) 0.19
BandWidth 31.28
MACD Line -0.09
MACD Signal Line 0.03
MACD Histogram -0.114
Fundamentals Value
Market Cap 1.37 Billion
Num Shares 260 Million
EPS -0.24
Price-to-Earnings (P/E) Ratio -22.00
Price-to-Sales 13.27
Price-to-Book 10.19
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.69
Resistance 3 (R3) 5.69 5.57 5.62
Resistance 2 (R2) 5.57 5.46 5.56 5.59
Resistance 1 (R1) 5.42 5.40 5.50 5.42 5.57
Pivot Point 5.30 5.30 5.33 5.29 5.30
Support 1 (S1) 5.15 5.19 5.23 5.15 4.99
Support 2 (S2) 5.03 5.13 5.02 4.97
Support 3 (S3) 4.88 5.03 4.94
Support 4 (S4) 4.88